Literature DB >> 7570743

L-deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia.

S Knollema1, W Aukema, H Hom, J Korf, G J ter Horst.   

Abstract

BACKGROUND AND
PURPOSE: L-Deprenyl (Selegiline) protects animal brains against toxic substances such as 1-methyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine. Experiments were conducted to test whether L-deprenyl prevents or reduces cerebral damage in a transient hypoxia/ischemia rat model.
METHODS: Rats were treated for 14 days with 2 mg/kg and 10 mg/kg L-deprenyl or saline. After surgery a 20-minute hypoxia/ischemia period was induced by simultaneous occlusion of the left common carotid artery and reduction of the percentage of oxygen in the gas mixture to 10%. Rats were killed 24 hours later. Silver staining was used to reveal damage in several brain regions.
RESULTS: In the brain, both L-deprenyl dosages reduced damage up to 78% compared with the controls. Total brain damage was decreased from 23%-31% to 5%-9% with the L-deprenyl treatment (2 mg/kg: F1.13 = 6.956, P < .05; 10 mg/kg: F1.13 = 5.731, P < .05). In the striatum, significant treatment effects were found between both the L-deprenyl groups (2 mg/kg and 10 mg/kg, respectively) and the saline group (F1.13 = 14.870, P < .005; and F1.13 = 8.937, P = .01; respectively). In the thalamus, significant treatment effects were seen in the 2-mg/kg L-deprenyl group (F1.13 = 11.638, P < .005) and the 10-mg/kg group (F1.13 = 8.347, P < .05) compared with the control group. No significant damage decrease was seen in the hippocampus and the cortex.
CONCLUSIONS: The results show that L-deprenyl is effective as a prophylactic treatment for brain tissue when it is administered before hypoxia/ischemia. Mechanisms responsible for the observed protection remain unclear. The regional differences in damage, however, are in accordance with the reported regional increase in superoxide dismutase and catalase activities after L-deprenyl treatment, suggesting the involvement of free radicals and scavenger enzymes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7570743     DOI: 10.1161/01.str.26.10.1883

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  8 in total

1.  Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion.

Authors:  K Grasing; R Azevedo; S Karuppan; S Ghosh
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

2.  Cell death/proliferation and alterations in glial morphology contribute to changes in diffusivity in the rat hippocampus after hypoxia-ischemia.

Authors:  Miroslava Anderova; Ivan Vorisek; Helena Pivonkova; Jana Benesova; Lydia Vargova; Michal Cicanic; Alexandr Chvatal; Eva Sykova
Journal:  J Cereb Blood Flow Metab       Date:  2010-09-29       Impact factor: 6.200

3.  Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat.

Authors:  Z Speiser; A Mayk; L Litinetsky; T Fine; A Nyska; E Blaugrund; S Cohen
Journal:  J Neural Transm (Vienna)       Date:  2006-12-21       Impact factor: 3.575

Review 4.  Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Authors:  Éva Szökő; Tamás Tábi; Peter Riederer; László Vécsei; Kálmán Magyar
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

5.  Neuroprotection by pharmacologic blockade of the GAPDH death cascade.

Authors:  Makoto R Hara; Bobby Thomas; Matthew B Cascio; Byoung-Il Bae; Lynda D Hester; Valina L Dawson; Ted M Dawson; Akira Sawa; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

Review 6.  Perspectives on MAO-B in aging and neurological disease: where do we go from here?

Authors:  M Jyothi Kumar; Julie K Andersen
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

7.  Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease.

Authors:  Kay Cheong Teo; Shu-Leong Ho
Journal:  Transl Neurodegener       Date:  2013-09-08       Impact factor: 8.014

8.  Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis.

Authors:  Cheng-Ming Tsao; Jhih-Gang Jhang; Shiu-Jen Chen; Shuk-Man Ka; Tao-Cheng Wu; Wen-Jinn Liaw; Hsieh-Chou Huang; Chin-Chen Wu
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.